Raisul Abedin, PhD, Senior Scientist at Adipo Therapeutics, delivered an oral presentation on the latest advancements in the treatment of obesity.
Presentation Title: Notch Signaling Inhibitor ADPO-002 Promotes Browning in Human Adipose Tissue Explants.
Key Takeaways:
- ADPO-002, a Notch inhibitor, promotes the expression of two key browning biomarkers (PRDM16 and PGC1a) in a study using adult human white adipose tissues supporting the translation of this novel mechanism of action in humans.
- PRDM16 and PGC1a are important in mitochondrial biogenesis and browning of white adipose tissue.
- ADPO-002 30-uM dose showed a 7-fold increase in PRDM16 (p value = 0.0001) and an 8-fold increase in PGC1a (p value = 0.0537) in subcutaneous adipose tissue samples.
- ADPO-002 30-uM dose also showed a 20-fold increase in PRDM16 (p value = 0.0002) and a 3-fold increase in PGC1a (p value = 0.0061) in omental adipose tissue samples.
- This is the first study to demonstrate the browning of human adult white adipose tissue through Notch inhibition and provides strong evidence that this novel mechanism of action translates to humans.